Regenxbio Inc. (NASDAQ:RGNX) Q4 2019 Earnings Conference Call - Final Transcript

Feb 26, 2020 • 04:30 pm ET


Regenxbio Inc. (NASDAQ:RGNX) Q4 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good afternoon, and welcome to the REGENXBIO Fourth Quarter and Full Year 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. As a reminder, this conference call is being recorded.

I would now like to turn the call over to Ms. Patrick Christmas, Senior Vice President and General Counsel for REGENXBIO, you may begin.

Patrick J. Christmas

Good afternoon, and thank you for joining us today. With us are Ken Mills, REGENXBIO's President and Chief Executive Officer; Dr. Steve Pakola, our Chief Medical Officer; and Vit Vasista, our Chief Financial Officer.

Earlier this afternoon, REGENXBIO released financial and operating results for the fourth quarter and full year ended December 31st, 2019. The press release reporting our financial results is available on our website at

Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted, and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management's Discussion and Analysis section of REGENXBIO's Annual Report on Form 10-K for the full year ended December 31, 2019, which will be filed with the Securities and Exchange Commission and available on the SEC's website.

Any information we provide on this conference call is provided only as of the date of this call, February 26, 2020, and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.

I would now like to turn the call over to Ken Mills, President and Chief Executive Officer of REGENXBIO.

Ken Mills

Thank you, Patrick. Good afternoon, everyone and thanks for joining us on today's conference call. We will provide a recap of our recent progress advancing and expanding the NAV technology platform as well as expected future milestones. Steve will provide an update of our clinical programs and Vit will provide an update on our financial results for the fourth quarter and the full year 2019. We'll then open the call for questions.

So over the course of the past decade, REGENXBIO's mission has remained clear to improve lives through the curative potential of gene therapy based on our proprietary NAV technology platform. We believe single administration gene therapy treatments can significantly alter the course of disease in many patient populations and we are advancing and broadening our